Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Använder rundstrålande virtuell verklighet och löpbandsträning för kronisk stroke (PROVE)

2 oktober 2026 uppdaterad av: Adria Quigley, Nova Scotia Health Authority

PROVE-VR: En slumpmässig pilotförsök med rundstrålande virtuell verklighet och löpbandsträning för överlevande av kroniska stroke

The primary objective of this pilot randomized controlled trial (RCT) is to test the feasibility (consent rate, retention rate, participant burden, adherence, technical issues, safety) and usability (system usability scale, SUS) of Omnidirectional treadmill Virtual Reality training (omni-VR) among chronic stroke survivors. Our secondary objective is to (1) estimate the extent to which cognition, brain activation during a dual task activity, walking ability, and dynamic balance change after 3 months of training among intervention participants (omni-VR) and traditional exercise controls, and (2) estimate the extent to which health-related quality of life and motivation co-evolve with our secondary outcomes.

Researchers will compare the intervention group and control group to evaluate the impact of omni-VR on cognition and physical function among stroke survivors.

Participants will:

  • undergo a 45-minute training session 3 times per week for 12 weeks
  • intervention group: omni-VR
  • control group: traditional exercise program (strengthening and walking activities)

Studieöversikt

Detaljerad beskrivning

Mounting data indicates that cognition plays a role in complex walking and balance. However, conventional intervention methods lack a sufficient incentive to encourage participants to adhere to the treatment. Further, it is difficult to provide a substantial amount of treatment to induce cortical reorganization.

Virtual reality or VR (a computer-generated simulation of 3-dimensional virtual environments that reacts in real time to the user's actions) has been introduced to neurorehabilitation to promote improvements in walking ability, balance, and cognition. It has also been demonstrated to be effective in improving motivation among stroke survivors and augmenting neuroplasticity.

Omnidirectional treadmill technology can be integrated with VR to allow for fully immersive rehabilitation. This novel and innovative technology mimics real-world environments and maximizes challenging cognitive and physical dual-tasking and balance activities while maintaining patient safety. However, no randomized trials have evaluated the impact of omnidirectional treadmill VR (Omni-VR) on cognitive and physical function among stroke survivors.

Therefore, our study aims to test the feasibility and usability of the Omni-VR. This pilot randomized control trial will also be the first study to test the feasibility and effect of a fully-immersive active omni-VR system among chronic stroke survivors

Studietyp

Interventionell

Inskrivning (Beräknad)

30

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 4K4
        • Rekrytering
        • Nova Scotia Rehabilitation & Arthritis Centre
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria

  • Age ≥ 18
  • Stroke ≥ 6 months ago (confirmed with chart review)
  • Living within 50 km of Halifax, Nova Scotia
  • Functional Ambulation Category of 3 or greater on a scale of 0-5, to ensure the participant is able to walk with supervision or independently. This criterion was selected to ensure participants could safely participate in the intervention.
  • Ability to participate in low-moderate intensity aerobic or strengthening exercise for ≥ 15 minutes to ensure participants can tolerate intervention sessions of 30-45 minutes, with activity breaks, in keeping with previous stroke rehabilitation studies.
  • No uncorrected visual deficits or spatial neglect
  • No cardiovascular, orthopedic, or neurological diseases other than stroke impacting walking or balance
  • Can follow simple instructions
  • Score of < 27 on the adapted Motion Sickness Susceptibility Scale-Short based on established normative values indicating more than moderate susceptibility to motion sickness.

Exclusion Criteria:

  • Unstable serious medical condition
  • Resting blood pressure >180/100mmHg
  • History of abnormal untreated heart rhythm
  • Pregnancy
  • Condition limiting ability to complete or tolerate the exercises without major program modifications (e.g., chronic low back pain)
  • Serious comorbid condition that would affect participation in the intervention (e.g., active cancer, severe heart disease)
  • Severe loss of hearing or speech that would preclude VR use
  • Participant weight more than 264 lbs (weight limit for Virtualizer Elite 2 treadmill)
  • Participating in another formal lower limb exercise program > 1 day per week
  • History of QT prolongation or using potential QT prolonging drugs

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Omni-VR group

20 participants will undergo 45-minute training sessions 3 times per week for 12 weeks using omnidirectional virtual reality and treadmill training.

Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie. stepping over obstacles, and managing distractions) will be used for treatment group.

Aktiv komparator: Control group

10 participants will undergo 45-minute traditional physiotherapy training sessions including lower limb strengthening and unidirectional treadmill training 3 times per week for 12 weeks.

A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Consent rate
Tidsram: Baseline

Consent rate is the percentage of eligible individuals who participate. The investigators expect a consent rate of at least 40%.

Baseline
Retention rate
Tidsram: 12 weeks (study completion)

Retention rate is the percentage of participants who complete the 12-week intervention. The investigators expect a retention rate of 80% for the intervention group.

12 weeks (study completion)
Usability of the Omnidirectional Treadmill and Virtual Reality Game
Tidsram: 12 weeks (study completion)

Usability will be assessed by System Usability Scale (SUS) out of 100 points. The investigators expect a SUS score of 71 or higher among all participants.

12 weeks (study completion)
Participant burden
Tidsram: Baseline and 12 weeks (study completion)

Participant burden will be measured by the percentage of participants finishing assessments in 100 minutes or less. The investigators anticipate at least 85% of participants completing assessments within the time limit.

Baseline and 12 weeks (study completion)
Adherence
Tidsram: 12 weeks (study completion)

Adherence will be measured by the exercise session attendance. The investigators expect the treatment group to attend 70% or more of the sessions.

12 weeks (study completion)
Equipment downtime
Tidsram: 12 weeks (study completion)

The investigators will record any treadmill downtime due to VR technical issues. The targets are zero significant downtime in 85% of sessions.

12 weeks (study completion)
Equipment safety
Tidsram: 12 weeks (study completion)

The investigators will record any serious adverse events related to the study. The target is no serious adverse events related to the study

12 weeks (study completion)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Cognitive function
Tidsram: Baseline and 12 weeks (study completion)

The investigators will use the Computerized MoCA [Montreal Cognitive Assessment] Duo to evaluate participants' cognitive function.

Baseline and 12 weeks (study completion)
Executive Function
Tidsram: Baseline and 12 weeks (study completion)

The investigators will use the Dimensional Change Card Sort to evaluate participants' executive function.

Baseline and 12 weeks (study completion)
Working memory
Tidsram: Baseline and 12 weeks (study completion)

The investigators will use the List Sorting Working Memory Test to evaluate participants' working memory.

Baseline and 12 weeks (study completion)
Brain activation in prefrontal and premotor cortices
Tidsram: Baseline and 12 weeks (study completion)

Brain activation using fNIRS [Functional near-infrared spectroscopy] in the prefrontal and premotor regions of interest during a single task (steady-state omnidirectional treadmill walking) and two cognitive-physical dual-task activities (simple dual-task: steady-state omnidirectional treadmill walking while repeating the same word and complex dual-task: steady-state omnidirectional treadmill walking while performing a verbal fluency test)

Baseline and 12 weeks (study completion)
Walking Speed
Tidsram: Baseline and 12 weeks (study completion)

Walking speed using VIVE trackers on omnidirectional treadmill and overground

Baseline and 12 weeks (study completion)
Step cadence
Tidsram: Baseline and 12 weeks (study completion)

The investigators will evaluate step cadence using the VIVE trackers.

Baseline and 12 weeks (study completion)
Step width
Tidsram: Baseline and 12 weeks (study completion)

The investigators will evaluate step width using the VIVE trackers.

Baseline and 12 weeks (study completion)
Step length
Tidsram: Baseline and 12 weeks (study completion)

The investigators will evaluate step length using the VIVE trackers.

Baseline and 12 weeks (study completion)
Dynamic balance
Tidsram: Baseline and 12 weeks (study completion)

The investigators will measure the static sway with feet together using omni-VR system and use MINI-BESTest to measure the dynamic balance.

Baseline and 12 weeks (study completion)

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Motivation of participant
Tidsram: 12 weeks (study completion)

The investigators will measure motivation by intrinsic motivation inventory. Higher scores indicate better results.

12 weeks (study completion)
Health-related quality of life of participant
Tidsram: Baseline and 12 weeks (study completion)

The investigators will measure health-related quality of life by the Stroke Impact Scale-3.0. Higher scores indicate better results.

Baseline and 12 weeks (study completion)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

28 april 2025

Primärt slutförande (Beräknad)

6 augusti 2027

Avslutad studie (Beräknad)

6 september 2027

Studieregistreringsdatum

Först inskickad

20 juni 2024

Först inskickad som uppfyllde QC-kriterierna

3 juli 2024

Första postat (Faktisk)

10 juli 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera